
Gotistobart Drug Shows Survival Benefit in Lung Cancer Trial
BioNTech reported that the drug candidate Gotistobart showed a clinically meaningful overall survival benefit for a specific form of lung cancer. The results came from the PRESERVE-003 Phase 3 clinical trial, which involved patients with squamous non-small cell lung cancer whose disease progressed despite prior immunotherapy and chemotherapy. Data were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer. According to one source, treatment with Gotistobart led to a statistically significant benefit, nearly doubling survival compared to standard-of-care chemotherapy in this patient group.














